Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH‐HCC guidelines) 2019 update
Author:
Affiliation:
1. The committee for Revision of the Clinical Practice Guidelines for Hepatocellular Carcinoma Tokyo Japan
Publisher
Wiley
Subject
Infectious Diseases,Hepatology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/hepr.13411
Reference17 articles.
1. Clinical practice guidelines for hepatocellular carcinoma: the first evidence based guidelines from Japan
2. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan
3. Clinical practice guidelines for hepatocellular carcinoma – The Japan Society of Hepatology 2009 update;Makuuchi M;Hepatol Res,2010
4. Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines)
5. Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Manual Proposed by the Japan Society of Hepatology
Cited by 389 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Osteosarcopenia impacts treatment outcomes for Barcelona Cancer Liver Classification stage A hepatocellular carcinoma;Surgical Oncology;2024-02
2. Comparison of six hepatocellular carcinoma prediction models in Japanese patients after sustained virologic response undergoing rigorous surveillance for hepatocellular carcinoma;Journal of Gastroenterology and Hepatology;2024-01-30
3. Exploratory prospective, randomized phase II study of neoadjuvant transcatheter arterial chemoembolization plus surgery versus surgery alone for large hepatocellular carcinoma (CSGO‐HBP‐005): Clinical Study Group of Osaka University, Hepato‐Biliary‐Pancreatic Group;Hepatology Research;2024-01-27
4. Lenvatinib Exacerbates the Decrease in Skeletal Muscle Mass in Patients with Hepatocellular Carcinoma, Whereas Atezolizumab Plus Bevacizumab Does Not;Cancers;2024-01-19
5. The adverse characteristics of hepatocellular carcinoma in the non‐cirrhotic liver disproportionately disadvantage Black patients;Cancer Medicine;2024-01-17
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3